{"id":"4c6966c7-2baa-5f20-877a-ebc33ad6fac0","stable_key":"4fef8d72-f107-5eb5-b2fb-483ca85465e0:k2-mk4-fractures-null","predicate":"did_not_significantly_reduce","statement":"Adding menatetrenone to calcium did not significantly reduce new vertebral fractures in the full analysis set; the clinical-fracture secondary difference was also nonsignificant.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"990dd8f6-4d47-53f5-b516-a5e448cbadfa","mechanism_event_label":"A large trial did not establish a general fracture-prevention benefit from adding MK-4.","subject":{"id":"5155b9d1-e835-54b4-9f61-4cf35b3e5227","slug":"menaquinone-4","display_name":"Menaquinone-4 / MK-4 / menatetrenone","entity_type_key":"small_molecule"},"object":{"id":"9dc6fb11-7036-52ea-bdf9-2269292df165","slug":"vertebral-fracture-incidence","display_name":"New vertebral fracture incidence","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"990dd8f6-4d47-53f5-b516-a5e448cbadfa","stable_key":"4fef8d72-f107-5eb5-b2fb-483ca85465e0:k2-mk4-fractures-null-event","event_type":"observed_intervention","label":"A large trial did not establish a general fracture-prevention benefit from adding MK-4.","description":"Adding menatetrenone to calcium did not significantly reduce new vertebral fractures in the full analysis set; the clinical-fracture secondary difference was also nonsignificant.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"8e2a5a1f-cd49-5f28-8611-325266fb78a6","slug":"calcium","display_name":"Calcium","entity_type_key":"nutrient_element"},"role":"shared_background","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5155b9d1-e835-54b4-9f61-4cf35b3e5227","slug":"menaquinone-4","display_name":"Menaquinone-4 / MK-4 / menatetrenone","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"9dc6fb11-7036-52ea-bdf9-2269292df165","slug":"vertebral-fracture-incidence","display_name":"New vertebral fracture incidence","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/k2-research/19082528.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"6d29b8f43348d8acd6ee85d4f65bb0cdd1352dd6f5113f58d7e58d7196bd96f5\", \"start_char\": 0, \"end_char\": 1657, \"text_sha256\": \"6d29b8f43348d8acd6ee85d4f65bb0cdd1352dd6f5113f58d7e58d7196bd96f5\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized open-label trial with blinded endpoint evaluation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Calcium alone versus calcium plus menatetrenone; 36-month primary and 48-month secondary endpoints","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Full-analysis null result; advanced-osteoporosis subgroup signals are exploratory and do not replace the overall endpoint.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"k2","display_name":"Vitamin K2 / menaquinone family","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"4378 osteoporotic postmenopausal women","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A large trial did not establish a general fracture-prevention benefit from adding MK-4.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[k2-p19082528] Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. (2009). https://pubmed.ncbi.nlm.nih.gov/19082528/ DOI: 10.1007/s00774-008-0008-8","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Vertebral and clinical fractures","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"406289b7-604c-5c96-b331-b4ca52a034cb","evidence_kind":"source_excerpt","locator":"Lines 1111-1122","start_line":1111,"end_line":1122,"excerpt":"### k2-mk4-fractures-null\nAdding menatetrenone to calcium did not significantly reduce new vertebral fractures in the full analysis set; the clinical-fracture secondary difference was also nonsignificant.\nCondition category: normal\nnutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A large trial did not establish a general fracture-prevention benefit from adding MK-4.\norganism: 4378 osteoporotic postmenopausal women\ntissue_or_cell_type: Vertebral and clinical fractures\nexperimental_model: Randomized open-label trial with blinded endpoint evaluation\nlimitations: Full-analysis null result; advanced-osteoporosis subgroup signals are exploratory and do not replace the overall endpoint.\nexposure: Calcium alone versus calcium plus menatetrenone; 36-month primary and 48-month secondary endpoints\nevidence_span: {\"source_cache\": \"artifacts/k2-research/19082528.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"6d29b8f43348d8acd6ee85d4f65bb0cdd1352dd6f5113f58d7e58d7196bd96f5\", \"start_char\": 0, \"end_char\": 1657, \"text_sha256\": \"6d29b8f43348d8acd6ee85d4f65bb0cdd1352dd6f5113f58d7e58d7196bd96f5\"}\n[k2-p19082528] Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. (2009). https://pubmed.ncbi.nlm.nih.gov/19082528/ DOI: 10.1007/s00774-008-0008-8","model_system":"Randomized open-label trial with blinded endpoint evaluation","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [k2-p19082528] Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. (2009). https://pubmed.ncbi.nlm.nih.gov/19082528/ DOI: 10.1007/s00774-008-0008-8","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dfeae572-af3d-5042-a10e-e67596f9ab28","stable_key":"import-4fef8d72-f107-5eb5-b2fb-483ca85465e0","title":"Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"dc31aff21110d09b025c177e03b4c5ca8349d52bf5f962285fdbfcf660c0e4f6","revision_id":"850887db-34f6-55aa-9d3e-b8fd3a4a5de3","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}